Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study ?>

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study 1

Oral OTEZLA(R) (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis. Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks; improvements continued through 32 weeks. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study. ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ESTEEM 1).

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study 2In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received placebo or apremilast (10, 20, or 30 mg BID). Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study. Categories: Psoriasis. Significantly more patients taking apremilast with moderate to severe palmoplantar psoriasis (baseline PPPGA score 3) achieved PPPGA score 0 (clear) or 1 (almost clear) compared with placebo at week 16 (48 vs 27; P. 2010; 3: 1 8CrossRef Scopus (1)See all References Patients with plaque psoriasis and palmoplantar psoriasis have greater functional disability and decrements in health-related quality of life compared with patients with plaque psoriasis lesions located elsewhere on the body. Pooled phase II PSOR-005 and phase III ESTEEM 1 and 2 studiesPlacebon 153Apremilast 30 mg twice dailyn 274TotalN 427Age, mean (SD), y47. Efalizumab in the treatment of scalp, palmoplantar and nail psoriasis: results of a 24-week Latin American study.

Fully published results of phase III studies of these agents are eagerly awaited. Nail psoriasis results from psoriatic involvement of the nail bed or nail matrix. Patients with nail psoriasis can develop a wide variety of nail ch. Data from two similar phase III, randomized, placebo-controlled studies evaluating the efficacy of apremilast for moderate to severe plaque psoriasis (ESTEEM 1 and ESTEEM 2) indicate that apremilast also improves nail psoriasis 63. Treatment with apremilast also resulted in significant improvement on patient-reported quality of life outcomes, with particular benefit noted at the 30 mg BID dose. Results from Phase 3 Studies in Plaque Psoriasis. As in ESTEEM 1, at Week 16, all patients receiving placebo were switched to apremilast 30 mg BID through Week 32, followed by a randomized withdrawal phase through Week 52.

Improvements In Patient-reported Outcomes With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In The Treatment Of Moderate To Severe Psoriasis: Results From A Phase Iib Randomized, Controlled Study

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study 3Several new agents to treat psoriasis are under study, including oral medications and injectable agents. Very early results show improvement in plaque psoriasis symptoms for many of these new therapies, but none of them are approved for use yet. The severity of the disease is also measured by its effect on a person’s quality of life. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study. Celgene International S rl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of. Leonardi CL,1 Mehta NN,2 Lebwohl M,3 Cooper S,4 Fox T5 1Saint Louis University Health Sciences Center, St. LIMITATIONS: Data for etanercept is available from only one phase 3 study. PA-06: Difference in patient reported psoriasis health-related quality of life between patients rated as ‘clear’ versus ‘almost clear’ based on physician global assessment. 1). Psoriasis of the nail bed presents as oil-drop discoloration, splinter hemorrhages involving the distal third of the nail plate, subungual hyperkeratosis, and/or detachment of the nail plate from the nail bed (onycholysis). The results of this study showed a significant time-effect improvement for pitting, onycholysis, hyperkeratosis, and salmon patches with both agents, without significant differences between the two investigated agents. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Koo J. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results. Effects of Atopic Dermatitis and Acne: A Review on Self-Esteem and Identity. Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib. What can U.S. dermatology learn from health care systems abroad?

Psoriasis